{"entity":{"type":"insider","cik":"0001811096","url":"/insider/0001811096","json_url":"/insider/0001811096.json","name":"Guyer Charles Greg","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":5,"n_filings":5,"first":"2022-08-10","last":"2026-03-12","span_basis":"filed_date"},"name_variants":[{"name":"Guyer Charles Greg","source":"filing","n_filings":5,"first_seen":"2022-08-10","last_seen":"2026-03-12"}],"transactions":[{"id":5787301,"accession":"0001628280-26-017447","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-26-017447","line_url":"/filing/0001628280-26-017447#line-1","is_derivative":false,"issuer_cik":"0001048477","issuer_name":"BIOMARIN PHARMACEUTICAL INC","issuer_ticker":"BMRN","issuer_name_source":null,"issuer_url":"/issuer/0001048477","owner_cik":"0001811096","owner_name":"Guyer Charles Greg","owner_display_name":"Guyer Charles Greg","owner_url":"/insider/0001811096","role":"Officer (EVP, Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16486.0,"shares_display":"16,486","price_per_share":60.46,"price_display":"60.46","price_state":"stated","total_value":996743.56,"total_display":"996,743.56","total_whole":"996,744","shares_owned_after":79953.0,"shares_owned_after_display":"79,953","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-11","filed_date":"2026-03-12","scope":"insider"},{"id":5160252,"accession":"0001048477-25-000025","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001048477-25-000025","line_url":"/filing/0001048477-25-000025#line-1","is_derivative":false,"issuer_cik":"0001048477","issuer_name":"BIOMARIN PHARMACEUTICAL INC","issuer_ticker":"BMRN","issuer_name_source":null,"issuer_url":"/issuer/0001048477","owner_cik":"0001811096","owner_name":"Guyer Charles Greg","owner_display_name":"Guyer Charles Greg","owner_url":"/insider/0001811096","role":"Officer (EVP, Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7034.0,"shares_display":"7,034","price_per_share":71.276,"price_display":"71.28","price_state":"stated","total_value":501355.384,"total_display":"501,355.38","total_whole":"501,355","shares_owned_after":87655.0,"shares_owned_after_display":"87,655","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-06","filed_date":"2025-03-07","scope":"insider"},{"id":2351716,"accession":"0001048477-24-000154","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001048477-24-000154","line_url":"/filing/0001048477-24-000154#line-2","is_derivative":false,"issuer_cik":"0001048477","issuer_name":"BIOMARIN PHARMACEUTICAL INC","issuer_ticker":"BMRN","issuer_name_source":null,"issuer_url":"/issuer/0001048477","owner_cik":"0001811096","owner_name":"Guyer Charles Greg","owner_display_name":"Guyer Charles Greg","owner_url":"/insider/0001811096","role":"Officer (EVP, Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5278.0,"shares_display":"5,278","price_per_share":66.3743,"price_display":"66.37","price_state":"stated","total_value":350323.5554,"total_display":"350,323.56","total_whole":"350,324","shares_owned_after":68909.0,"shares_owned_after_display":"68,909","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-12","filed_date":"2024-11-14","scope":"insider"},{"id":8646927,"accession":"0001048477-23-000035","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001048477-23-000035","line_url":"/filing/0001048477-23-000035#line-1","is_derivative":false,"issuer_cik":"0001048477","issuer_name":"BIOMARIN PHARMACEUTICAL INC","issuer_ticker":"BMRN","issuer_name_source":null,"issuer_url":"/issuer/0001048477","owner_cik":"0001811096","owner_name":"Guyer Charles Greg","owner_display_name":"Guyer Charles Greg","owner_url":"/insider/0001811096","role":"Officer (EVP, Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5360.0,"shares_display":"5,360","price_per_share":93.304,"price_display":"93.30","price_state":"stated","total_value":500109.44,"total_display":"500,109.44","total_whole":"500,109","shares_owned_after":40041.0,"shares_owned_after_display":"40,041","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-09","filed_date":"2023-08-10","scope":"insider"},{"id":6952588,"accession":"0001567619-22-015499","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-015499","line_url":"/filing/0001567619-22-015499#line-1","is_derivative":false,"issuer_cik":"0001048477","issuer_name":"BIOMARIN PHARMACEUTICAL INC","issuer_ticker":"BMRN","issuer_name_source":null,"issuer_url":"/issuer/0001048477","owner_cik":"0001811096","owner_name":"Guyer Charles Greg","owner_display_name":"Guyer Charles Greg","owner_url":"/insider/0001811096","role":"Officer (EVP, Chief Technical Officer)","role_mark":"O","role_mark_label":"Officer (EVP, Chief Technical Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Chief Technical Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6205.0,"shares_display":"6,205","price_per_share":96.56,"price_display":"96.56","price_state":"stated","total_value":599154.8,"total_display":"599,154.80","total_whole":"599,155","shares_owned_after":42168.0,"shares_owned_after_display":"42,168","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-08","filed_date":"2022-08-10","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":5,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":5,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":5},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001048477","name":"BIOMARIN PHARMACEUTICAL INC","url":"/issuer/0001048477","role":"Officer (EVP, Chief Technical Officer)","n_filings":5,"first_seen":"2022-08-10","last_seen":"2026-03-12"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001811096","retrieved_at":"2026-08-27T05:02:23+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}